pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,034 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT797Endpoints601BioPharma Dive231onclive165Fierce Biotech72BioSpace69raps29
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more
    The question of whether to partner with Chinese firms — or see them as rivals — is tearing biotech apart, pitting peers and partners against one another
    STAT · 2mo ago↗ source
  • Texas is opening up a detransition clinic
    Americans exposed to Ebola outbreak, Bill Cassidy's primary defeat, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
  • Opinion: ‘Patient autonomy’ has nothing to do with childhood vaccine policies
    Opinion: Vaccine policy it is not a matter of autonomy at all, because infants do not decline vaccination — their parents do.
    STAT · 2mo ago↗ source
← prev
page 25 of 42
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • STAT+: The China question is tearing biotech apart
    China's ascent is forcing U.S. biotech companies and investors to pick a side: Is it an ally or an existential threat?
    STAT · 2mo ago↗ source
  • Opinion: How to restore credibility to the CDC’s vaccine advisory committee
    Jesse Goodman, former director of CBER and former FDA chief scientist, calls for five critical changes to restore trust in the Advisory Committee on Immunization Practices.
    STAT · 2mo ago↗ source
  • STAT+: U.K. advocacy groups threaten court action over a key provision in the pharma trade deal with the U.S.
    A pair of advocacy groups is threatening legal action unless the U.K. government revokes regulations at the heart of a new pharma trade agreement with the U.S.
    STAT · 2mo ago↗ source
  • In Ebola outbreak, a number of Americans in the Congo believed to have had exposure to suspected cases
    A number of Americans who are in the Congo are believed to have had exposure to suspected cases in the country’s latest Ebola outbreak, sources have told STAT.
    STAT · 2mo ago↗ source
  • When should you get a mammogram? Conflicting advice makes it hard to know
    When should you get a mammogram? Conflicting advice makes it hard to know.
    STAT · 2mo ago↗ source
  • STAT+: The hantavirus outbreak is prompting Covid flashbacks — including the conspiracies
    The deadly outbreak of a rare strain of hantavirus on a cruise has generated echoes of the pandemic era, including conspiracy theories.
    STAT · 2mo ago↗ source
  • STAT+: Sen. Bill Cassidy loses primary as race heads to run-off in win for Trump
    Key health lawmaker Sen. Bill Cassidy will lose his seat, as Louisiana’s Senate primary heads for a runoff between state treasurer John Fleming and Trump-backed Rep. Julia Letlow.
    STAT · 2mo ago↗ source
  • WHO declares Ebola outbreak an international public health emergency
    The WHO said an Ebola outbreak first seen in the Democratic Republic of the Congo was an international public health emergency, underscoring the world's concerns.
    STAT · 2mo ago↗ source
  • <![CDATA[Dr Meeks on a Real-World Study of BCG Retreatment After BCG Failure in NMIBC]]>
    <![CDATA[Joshua J. Meeks, MD, PhD, discusses data from a real-world study of BCG retreatment after BCG failure in NMIBC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Hafron on a Multidisciplinary Quality Initiative Designed to Mitigate the AEs of ADT in Prostate Cancer]]>
    <![CDATA[Jason Hafron, MD, discusses findings from a study that evaluated the implementation of a multidisciplinary quality initiative in prostate cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Preoperative Intravesical Mitomycin-C Before TURBT Cuts Recurrence Risk by 77% in NMIBC Over 5 Years]]>
    <![CDATA[Two doses of intravesical mitomycin-C administered before TURBT produced a 77% reduction in the risk of recurrence or death vs TURBT alone in NMIBC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Genomic Disease Burden Markers, PD-L1 Expression Predictive of pOR With Neoadjuvant Gem-iDRS ± Cetrelimab in MIBC]]>
    <![CDATA[A biomarker analysis of SunRISe-4 found that high baseline TMB, GBD, and PD-L1 expression were associated with pathologic overall response to the regimen. ]]>
    onclive · 2mo ago↗ source
  • Trump blasts ‘disloyal’ Sen. Cassidy while pushing challenger in Louisiana Republican primary
    Bill Cassidy, leader of the Senate committee that oversees health policy, is fighting for his political life in Louisiana's Republican primary on Saturday.
    STAT · 2mo ago↗ source
  • Opinion: The cloudy truth about ‘blue zones’
    “There's been interest in longevity, promoting it, for millennia. But this 25-year campaign really brought it to the forefront,” Eric Topol says of blue zones.
    STAT · 2mo ago↗ source
  • Opinion: Marty Makary misunderstood something fundamental about the FDA
    “The norm-shattering masks a more fundamental misunderstanding of how administrative power can bring about lasting change,” writes Joshua Sharfstein.
    STAT · 2mo ago↗ source
  • <![CDATA[Dr Croll on Radiographic Size Change vs irRVT After Neoadjuvant Therapy in RCC]]>
    <![CDATA[Benjamin Croll, MD, discusses findings from a study of the correlation between radiographic response and pathologic response in RCC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Approves T-DXd for Early-Stage HER2+ Breast Cancer]]>
    <![CDATA[The FDA approved trastuzumab deruxtecan for the adjuvant and neoadjuvant treatment of select early-stage HER2-positive breast cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Garzotto on Aglatimagene Besadenovec Plus Valacyclovir and EBRT in Localized Prostate Cancer]]>
    <![CDATA[Mark Garzotto, MD, discusses efficacy data with aglatimagene besadenovec plus valacyclovir and EBRT in localized prostate cancer.]]>
    onclive · 2mo ago↗ source
  • STAT+: FDA leadership shakeup widens following Makary’s departure
    The acting director of the FDA’s drug center, Tracy Beth Høeg, is leaving the agency. The news come days after Commissioner Marty Makary handed in his resignation.
    STAT · 2mo ago↗ source
  • <![CDATA[Dr Cirstea on Sequencing Considerations in R/R Multiple Myeloma]]>
    <![CDATA[Diana Cirstea, MD, discusses sequencing considerations in relapsed/refractory multiple myeloma in the era of T-cell–redirecting therapies.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Hafron on the FDA Approval of Adjuvant Atezolizumab in MRD+ MIBC]]>
    <![CDATA[Jason Hafron, MD, discusses the significance of the FDA approval of adjuvant atezolizumab for MRD+ muscle-invasive bladder cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Durvalumab Plus BCG Reduces High-Risk NMIBC Recurrence or Death Risk by 32% in Phase 3 POTOMAC Trial]]>
    <![CDATA[Durvalumab plus BCG induction and maintenance yielded an HR of 0.68 vs BCG alone for DFS in BCG-naive, high-risk non–muscle-invasive bladder cancer.]]>
    onclive · 2mo ago↗ source